Orum Therapeutics, Inc.
KOSDAQ-listed biotech developing its TPD² (Dual-precision Targeted Protein Degradation) DAC platform, led by its GSPT1-targeting degrader candidate.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2016 and listed on KOSDAQ in 2025, Orum Therapeutics is a biotech specializing in antibody-drug conjugate (ADC) and targeted protein degradation (TPD) technology. It has developed the TPD² (Dual-precision Targeted Protein Degradation, DAC) platform combining ADC and TPD technologies, and based on this built the TPD²-GSPT1 platform targeting the GSPT1 (G1 to S phase transition 1) protein with its proprietary payload SMol006. TPD²-GSPT1 delivers the degrader selectively to cancer cells via the antibody, which has been shown to increase efficacy more than 1,000-fold compared to small-molecule TPD drugs.
R&D and key agreements
Source: DART corporate disclosureTPD²(Dual-precision Targeted Protein Degradation) · 플랫폼 기술 · DAC platform combining ADC and targeted protein degradation technology
TPD²-GSPT1 · 플랫폼/후보물질 · GSPT1-targeting degrader payload (SMol006); shown to increase efficacy over 1000-fold versus small-molecule TPD drugs
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- PerplexityPerplexityBot1
Measured since Aug 25, 2026 · 1 AI engines · last read Aug 25, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition